RXi Q1 Loss Up on Slightly Higher Expenses | GenomeWeb

NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week reported a slight increase in its first-quarter net loss on modestly higher costs.

For the three-month period ended March 31, 2014, RXi's net loss was $2.3 million, up from $2.1 million in the year-ago quarter. The first-quarter 2013 loss does not include the impact of a one-time charge of $12.3 million related to the company's acquisition of Opko Health's RNAi assets.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.